Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Dr. Reddy's Is Set To Launch A Fourth Biosimilar - Pegfilgrastim

This article was originally published in The Pink Sheet Daily

Executive Summary

With filgrastim, rituximab and darbepoetin alfa already under its belt, Dr. Reddy's says it has seven more products - the bulk of which are thought to be copies of established monoclonal antibodies - in early development and preclinical testing.

You may also be interested in...



Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More

MUMBAI - Dr. Reddy's Labs has become the world's first company to launch a generic version of Amgen's erythropoiesis-stimulating agent Aranesp (darbepoetin alfa). The biosimilar, called Cresp, has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy, Dr. Reddy's announced Aug. 9

After Launching First Pegylated GCSF, Intas Biopharma Examines Technology For Pegylated Erythropoietin

MUMBAI - Ahmedabad, India-based biotech firm Intas Biopharma is looking at commencing research on a generic form of pegylated erythropoietin

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

PS072177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel